Direct and Retrograde Transduction of Nigral Neurons with AAV6, 8, and 9 and Intraneuronal Persistence of Viral Particles
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated viral (AAV) vectors of serotypes 6, 8, and 9 were characterized as tools for gene delivery to dopaminergic neurons in the substantia nigra for future gene therapeutic applications in Parkinson's disease. While vectors of all three serotypes transduced nigral dopaminergic neurons with equal efficiency when directly injected to the substantia nigra, AAV6 was clearly superior to AAV8 and AAV9 for retrograde transduction of nigral neurons after striatal delivery. For sequential transduction of nigral dopaminergic neurons, the combination of AAV9 with AAV6 proved to be more powerful than AAV8 with AAV6 or repeated AAV6 administration. Surprisingly, single-stranded viral genomes persisted in nigral dopaminergic neurons within cell bodies and axon terminals in the striatum, and intact assembled AAV capsid was enriched in nuclei of nigral neurons, 4 weeks after virus injections to the substantia nigra. 6-Hydroxydopamine (6-OHDA)-induced degeneration of dopaminergic neurons in the substantia nigra reduced the number of viral genomes in the striatum, in line with viral genome persistence in axon terminals. However, 6-OHDA-induced axonal degeneration did not induce any transsynaptic spread of AAV infection in the striatum. Therefore, the potential presence of viral particles in axons may not represent an important safety issue for AAV gene therapy applications in neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456 · cited 4×
“AAV9, after striatal injections displayed a neuronal, but not astrocytic or oligodendrocytic tropism, also previously reported for mice after striatal or cortical injections of AAV9 (Cearley and Wolfe, 2006; Foust et al. , 2009).”
InfluentialBoutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease
Christine, C. W., Starr, P. A., Larson, P. S., Eberling, J. L., Jagust, W. J., Hawkins, R. A., VanBrocklin, H. F., Wright, J. F., Bankiewicz, K. S., & Aminoff, M. J. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c29356 · Cited by 445 · cited 3×
“AAV2 is currently the most frequently used serotype in gene therapy for the central nervous system (Christine et al. , 2009; Marks et al. , 2010; Diaz-Nido, 2010; Fitzsimons et al. , 2010; Muramatsu et al. , 2010; Valles et al. , 2010), a major drawback being the widespread pre-existing immunity in…”
Results from a phase I safety trial of hAADC gene therapy for Parkinson disease
Eberling, J. L., Jagust, W. J., Christine, C. W., Starr, P., Larson, P., Bankiewicz, K. S., & Aminoff, M. J. (2008) · Neurology · doi:10.1212/01.wnl.0000312381.29287.ff · Cited by 370 · cited 1×
“…aiming at dopamine restoration through expression of dopamine-synthesizing enzymes in striatal neurons (During et al. , 1998; Wang et al. , 2002; Eberling et al. , 2008; Christine et al. , 2009; Jarraya et al. , 2009; Muramatsu et al. , 2010; Valles et al. , 2010), and also in gene therapeutic…”
Grimm, D., Kay, M. A., & Kleinschmidt, J. A. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00095-9 · Cited by 344 · cited 2×
“…(kindly provided by Dr. J. Kleinschmidt, Deutsches Krebsforschungs-zentrum, Heidelberg, Germany) were generated by exchange of the cap gene in pDF5 (Grimm et al. , 2003) with the AAV8 or AAV9 cap genes (Gao et al. , 2002, 2004) and were used for production of AAV2/8 and AAV2/9 particles,…”
A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson’s disease
Muramatsu, S.-I., Fujimoto, K.-I., Kato, S., Mizukami, H., Asari, S., Ikeguchi, K., Kawakami, T., Urabe, M., Kume, A., Sato, T., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.135 · Cited by 344 · cited 3×
“…frequently used serotype in gene therapy for the central nervous system (Christine et al. , 2009; Marks et al. , 2010; Diaz-Nido, 2010; Fitzsimons et al. , 2010; Muramatsu et al. , 2010; Valles et al. , 2010), a major drawback being the widespread pre-existing immunity in the human population (72”
Adeno-Associated Virus Serotype 9 Transduction in the Central Nervous System of Nonhuman Primates
Samaranch, L., Salegio, E. A., San Sebastian, W., Kells, A. P., Foust, K. D., Bringas, J. R., Lamarre, C., Forsayeth, J., Kaspar, B. K., & Bankiewicz, K. S. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.200 · Cited by 299 · cited 1×
“In contrast, AAV9 tail vein injections in adult mice and injections into the internal carotid artery or into the cisterna magna in nonhuman primates, resulted in a predominantly astrocytic tropism (Foust et al. , 2009; Samaranch et al. , 2012).”
Douar, A.-M., Poulard, K., Stockholm, D., & Danos, O. (2001) · Journal of Virology · doi:10.1128/jvi.75.4.1824-1833.2001 · Cited by 282 · cited 2×
“In these studies proteasome inhibition led to an increased number of AAV genomes per cell and accumulation of intact recombinant AAV within the nucleus, which resulted in an increased transduction efficiency (Douar et al., 2001; Denby et al., 2005; Johnson and Samulski, 2009; Johnson et al., 2010).”
Jacobson, S. G., Acland, G. M., Aguirre, G. D., Aleman, T. S., Schwartz, S. B., Cideciyan, A. V., Zeiss, C. J., Komaromy, A. M., Kaushal, S., Roman, A. J., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.005 · Cited by 224 · cited 1×
“Further evidence for axonal and transsynaptic transport of AAV comes from reports stating the presence of vector DNA along the visual pathway after intravitreal and subretinal injection of AAV2/ 2 in dogs and rats (Provost et al. , 2005; Jacobson et al. , 2006).”
Yan, Z., Zak, R., Luxton, G. W. G., Ritchie, T. C., Bantel-Schaal, U., & Engelhardt, J. F. (2002) · Journal of Virology · doi:10.1128/jvi.76.5.2043-2053.2002 · Cited by 222
Cited by
Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality
Hudry, E., & Vandenberghe, L. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.017 · Cited by 369
The RNA-Binding Protein PUM2 Impairs Mitochondrial Dynamics and Mitophagy During Aging
D’Amico, D., Mottis, A., Potenza, F., Sorrentino, V., Li, H., Romani, M., Lemos, V., Schoonjans, K., Zamboni, N., Knott, G., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.11.034 · Cited by 159
“Adeno associated virus (AAV) production—Recombinant serotype 9 adenoassociated viral (AAV) vectors were produced according to standard procedures, as described in (Löw et al., 2013).”
MethodSelf-citationParkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration
Tsika, E., Glauser, L., Moser, R., Fiser, A., Daniel, G., Sheerin, U.-M., Lees, A., Troncoso, J. C., Lewis, P. A., Bandopadhyay, R., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu178 · Cited by 159
“Female adult Sprague-Dawley rats (Charles River Laboratories, France) weighing 180–200 g received a viral titer of 5 × 10 6 TUs (in a 2 m l volume), unilaterally, at coordinates corresponding to the rat substantia nigra, as previously described (36).”
MethodSelf-citationGlymphatic fluid transport controls paravascular clearance of AAV vectors from the brain
Murlidharan, G., Crowther, A., Reardon, R. A., Song, J., & Asokan, A. (2016) · JCI Insight · doi:10.1172/jci.insight.88034 · Cited by 72
Succinic Semialdehyde Dehydrogenase Deficiency: An Update
Didiasova, M., Banning, A., Brennenstuhl, H., Jung-Klawitter, S., Cinquemani, C., Opladen, T., & Tikkanen, R. (2020) · Cells · doi:10.3390/cells9020477 · Cited by 52
Fajardo-Serrano, A., Rico, A. J., Roda, E., Honrubia, A., Arrieta, S., Ariznabarreta, G., Chocarro, J., Lorenzo-Ramos, E., Pejenaute, A., Vázquez, A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126389 · Cited by 32
“grade spread, AAV6 and AAV9 in particular [61,128], newly-designed AAV capsid vari-”
Background
Metadata
- Authors
- Löw, K., Aebischer, P., & Schneider, B. L.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2013-06
- Volume
- 24
- Issue
- 6
- Pages
- 613-629
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W1980962724
- Cited by
- 50
- References
- 20
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.